echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Prevalence of COVID-19 in patients with chronic inflammatory and autoimmune rheumatism

    Ann Rheum Dis: Prevalence of COVID-19 in patients with chronic inflammatory and autoimmune rheumatism

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The risk or benefit of COVID-19 susceptibility and immunosuppressive therapy in patients with rheumatism is not yet knownThe researchers conducted a retrospective study of patients in the rheumatology department at seven Spanish hospitalsThe latest database of patients with rheumatism patients who tested positive for severe acute respiratory syndrome coronavirus 2 by hospital PCR was matched with the same reference populationThe ratio of COVID-19 was compared with PCR plus confirmed in each groupThe prevalence of PCR-COVID-19 in hospitals with chronic inflammatory diseases was 1.32 times higher than in the reference population (0.76% vs 0.58%)The prevalence of PCR-COVID-19 increased significantly in patients with systemic autoimmune or immunomediated disease (AI/IMID), but no increase in COVID-19 in patients with inflammatory arthritis (IA) or systemic lupusIn some but not all diagnostic groups, COVID-19 cases are older than the reference populationThe prevalence of COVid-19 increased in Patients with IA who received targeted synthetic or biological disease-improving anti-rheumatoid drugs (DMARDs) and did not increase in IA patients receiving conventional lysined DMARDs, despite similar age distributionsThe risk of AI/IMID patients being diagnosed with COVID-19 in hospital stakes are differentThe interaction of age, treatment and disease-specific factors has an impact on the risk of diseaseThese data provide a basis for improved preventive recommendations for patients with rheumatism and for the analysis of specific factors related to COVID-19 susceptibility
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.